Breaking News Instant updates and real-time market news.

2020-12-11 08:17:20 SCYX Scynexis $7.45 / +0.02 (+0.27%) 08:17 12/11/20 12/11 08:17 12/11/20 08:17	IV formulation of ibrexa 'a significant positive' for Scynexis, says Maxim Maxim analyst Jason McCarthy noted that Scynexis announced that the intravenous, or IV, liposomal formulation of antifungal candidate ibrexa is moving into a Phase 1 study in Q1, which he views as a "significant positive." The news represents the resolution of the IV-related issues from several years ago, while the IV option with step down to oral for an antifungal is "very important," McCarthy contends. The remergence of IV ibrexa back to the clinic "enhances the story," said McCarthy, who keeps a Buy rating and $15 price target on Scynexis shares.	01 Jun

2020-12-11 08:17:20

SCYX

Scynexis

$7.45 / +0.02 (+0.27%)

08:17

12/11/20

12/11

08:17

12/11/20

08:17

IV formulation of ibrexa 'a significant positive' for Scynexis, says Maxim

Maxim analyst Jason McCarthy noted that Scynexis announced that the intravenous, or IV, liposomal formulation of antifungal candidate ibrexa is moving into a Phase 1 study in Q1, which he views as a "significant positive." The news represents the resolution of the IV-related issues from several years ago, while the IV option with step down to oral for an antifungal is "very important," McCarthy contends. The remergence of IV ibrexa back to the clinic "enhances the story," said McCarthy, who keeps a Buy rating and $15 price target on Scynexis shares.

01
Jun

TODAY'S FREE FLY STORIES

Hot Stocks	Fifth Third expects to repurchase up to $180M in Q1 » 07:11 01/21/21 01/21 07:11 01/21/21 07:11 FITB Fifth Third $31.32 / -0.75 (-2.34%) Comments taken from Q4… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events FITB Fifth Third $31.32 / -0.75 (-2.34%) 06:39 Today Fifth Third CEO says capital, liquidity levels 'further improved' in Q4 06:32 Today Fifth Third reports Q4 net interest margin 2.58% vs. 3.27% a year ago 01/04/21 Fifth Third completes acquisition of Hammond Hanlon Camp 12/07/20 Fifth Third Bank announces $2.8B investment to accelerate racial equity FITB Fifth Third $31.32 / -0.75 (-2.34%) 01/07/21 Goldman Sachs Fifth Third upgraded to Buy from Neutral at Goldman Sachs 01/06/21 Deutsche Bank Fifth Third price target raised to $30 from $24 at Deutsche Bank 01/04/21 Barclays Fifth Third price target raised to $37 from $28 at Barclays 12/07/20 Evercore ISI Fifth Third upgraded to In Line from Underperform at Evercore ISI FITB Fifth Third $31.32 / -0.75 (-2.34%) 06:31 Today Fifth Third reports Q4 EPS 78c, consensus 69c 10/22/20 Fifth Third reports Q3 EPS 78c, consensus 60c 10/21/20 Notable companies reporting before tomorrow's open 10/21/20 Notable companies reporting before tomorrow's open FITB Fifth Third $31.32 / -0.75 (-2.34%) 01/20/21 Notable companies reporting before tomorrow's open 01/20/21 Notable companies reporting before tomorrow's open 11/21/20 Citizens Financial, Truist among regional bank stocks to grab, Barron's says 08/15/20 PNC, KeyCorp among large regional banks offering steady dividends, Barron's says FITB Fifth Third $31.32 / -0.75 (-2.34%) 09/25/20 Cruise Line upgrades among today's top calls on Wall Street 09:00 Today Fifth Third - FITB
Hot Stocks	Climb Channel Solutions launches Climb Elevate » 07:11 01/21/21 01/21 07:11 01/21/21 07:11 WSTG Wayside Technology $19.57 / +0.11 (+0.57%) Climb Channel Solutions… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News WSTG Wayside Technology $19.57 / +0.11 (+0.57%) 01/19/21 Climb Channel Solutions partners with ChannelOnline 01/12/21 TechXtend, Resiliency Technologies announce national partnership 12/14/20 Climb Channel Solutions appoints Charles Bass as CMO 12/03/20 Climb Channel Solutions to distribute SUSE's open source solutions
Recommendations	Cinedigm price target raised to $3 from $2 at Alliance Global Partners » 07:10 01/21/21 01/21 07:10 01/21/21 07:10 CIDM Cinedigm $1.21 / +0.12 (+11.01%) Alliance Global Partners… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research CIDM Cinedigm $1.21 / +0.12 (+11.01%) 01/19/21 Cinedigm acquires Fandor, terms not disclosed 12/08/20 Cinedigm, Spherex partner on global content localization, compliance 11/30/20 Cinedigm acquires over 1,000 hours of premium film, TV programming 11/19/20 Cinedigm launching Whistle TV streaming channel on Roku Channel CIDM Cinedigm $1.21 / +0.12 (+11.01%) 10/16/20 Alliance Global Partners Cinedigm initiated with a Buy at Alliance Global Partners 07/07/20 Benchmark Cinedigm initiated with a Speculative Buy at Benchmark 07/07/20 Benchmark Cinedigm initiated with a Speculative Buy at Benchmark
Recommendations	Booking Holdings price target raised to $2480 from $2120 at Truist » 07:10 01/21/21 01/21 07:10 01/21/21 07:10 BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) Truist analyst Naved Khan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) 11/16/20 Lone Pine buys Square, exits Visa in Q3 10/14/20 Eightfold.ai to modernize Booking.com's global talent acquisition processes 09/10/20 Booking Holdings to reduce Booking.com's global workforce by about 10% 08/17/20 Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) 01/08/21 Mizuho Booking Holdings price target raised to $2,345 from $2,020 at Mizuho 01/04/21 Fly Intel: Top five analyst initiations 01/04/21 Loop Capital Booking Holdings initiated with a Hold at Loop Capital 01/04/21 Deutsche Bank Booking Holdings price target raised to $2,585 from $1,985 at Deutsche Bank BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) 11/05/20 Booking CEO says COVID-19 surge to impact travel in near-term 11/05/20 Booking Holdings reports Q3 adjusted EPS $12.27, consensus $14.13 11/05/20 Notable companies reporting after market close 08/06/20 Booking Holdings reports Q2 adjusted EPS ($10.81), consensus ($11.70) BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) 09/29/20 Amazon gets into virtual tourism, with Amazon Explore, GeekWire reports BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) 01/04/21 Airbnb under pressure as Wall Street analysts roll out coverage following IPO 12/14/20 Disney, Airbnb downgrades among today's top calls on Wall Street 12/10/20 Tesla downgrade, Disney initiation among today's top calls on Wall Street 12/01/20 Pinterest, FedEx upgrades among today's top calls on Wall Street BKNG Booking Holdings $2,160.05 / -6.04 (-0.28%) 01/04/21 Booking Holdings put volume heavy and directionally bearish 09/03/20 Booking Holdings put volume heavy and directionally bearish
Hot Stocks	Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board » 07:09 01/21/21 01/21 07:09 01/21/21 07:09 CERE Cerevel Therapeutics $14.36 / -0.13 (-0.90%) , PFE Pfizer $36.48 / -0.26 (-0.71%) Cerevel Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CERE PFE CERE Cerevel Therapeutics $14.36 / -0.13 (-0.90%) 01/19/21 Inspire appoints Bryan Phillips as chief compliance officer, general counsel 01/19/21 Frequency Therapeutics appoints Quentin McCubbin as chief manufacturing officer 12/08/20 Cerevel Therapeutics appoints Ruth McKernan to board of directors 10/30/20 Cerevel Therapeutics doses first patients in Phase 3 trials of tavapadon PFE Pfizer $36.48 / -0.26 (-0.71%) 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 01/13/21 Siga Technologies: Meridian Medical to purchase up to $33M of oral TPOXX CERE PFE CERE Cerevel Therapeutics $14.36 / -0.13 (-0.90%) 12/10/20 Goldman Sachs Cerevel Therapeutics initiated with a Buy at Goldman Sachs 11/23/20 Jefferies Cerevel Therapeutics initiated with a Buy at Jefferies 11/09/20 Fly Intel: Top five analyst initiations 11/09/20 Stifel Cerevel Therapeutics initiated with a Buy at Stifel PFE Pfizer $36.48 / -0.26 (-0.71%) 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg PFE PFE Pfizer $36.48 / -0.26 (-0.71%) 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 PFE PFE Pfizer $36.48 / -0.26 (-0.71%) 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports 01/20/21 Pfizer/BioNTech vaccine likely to be effective against Covid variant, FT reports 01/18/21 NY Gov. asks Pfizer to directly sell COVID vaccine doses, Reuters reports CERE PFE CERE Cerevel Therapeutics $14.36 / -0.13 (-0.90%) 11/16/20 Fly Insider: Cerevel Therapeutics, Paylocity among weeks notable insider trades PFE Pfizer $36.48 / -0.26 (-0.71%) 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 02/08/21 17th Annual Virtual WORLDSymposium 2021 02/02/21 Pfizer - PFE 01/24/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 PFE PFE Pfizer $36.48 / -0.26 (-0.71%) 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th

Initiation	SolarEdge initiated with an Overweight at Morgan Stanley » 07:09 01/21/21 01/21 07:09 01/21/21 07:09 SEDG SolarEdge $297.20 / +2.11 (+0.72%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SEDG SolarEdge $297.20 / +2.11 (+0.72%) 12/23/20 SolarEdge appoints Yogev Barak as Chief Marketing Officer 11/02/20 SolarEdge falls 12% to $234.44 after below-consensus Q3 revenue, Q4 guidance 09/01/20 SolarEdge reports Avida resigns from board of directors 08/03/20 SolarEdge up 11.5% at $193.50 per share after Q2 earnings beat and guidance SEDG SolarEdge $297.20 / +2.11 (+0.72%) 01/20/21 JPMorgan SolarEdge price target raised to $387 from $371 at JPMorgan 01/20/21 Credit Suisse SolarEdge price target raised to $284 from $235 at Credit Suisse 01/19/21 Goldman Sachs Buy the dip on Enphase Energy after Tesla inverter news, says Goldman Sachs 01/19/21 Piper Sandler SolarEdge price target raised to $340 from $325 at Piper Sandler SEDG SolarEdge $297.20 / +2.11 (+0.72%) 11/02/20 SolarEdge sees Q4 revenue $345M-$365M, consensus $389.57M 11/02/20 SolarEdge reports Q3 EPS $1.21, consensus 82c 08/03/20 SolarEdge sees Q3 revenue $325M-$350M, consensus $330.76M 08/03/20 SolarEdge reports Q2 EPS 97c, consensus 69c SEDG SolarEdge $297.20 / +2.11 (+0.72%) 01/16/21 Charged: NIO unveils new sedan, Plug partners with Renault 01/09/21 Charged: Apple self-driving EV said to be years away 12/26/20 Charged: Apple's potential EV entry seen as 'Tesla bear case' 12/26/20 Week in review: How Trump's policies moved stocks 11:00 Today Energy - Residential Solar
Hot Stocks	Travelers reports Q4 consolidated combined ratio of 86.7% » 07:09 01/21/21 01/21 07:09 01/21/21 07:09 TRV Travelers $145.04 / +1.5 (+1.05%) In Q4: Consolidated… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events TRV Travelers $145.04 / +1.5 (+1.05%) 06:58 Today Travelers reports book value per share of $115.68, up 14% from year-end 2019 12/03/20 Travelers acquires InsuraMatch from Plymouth Rock Group, terms not disclosed 10/20/20 Travelers CEO says net written premiums in Q3 up nearly 3% 10/20/20 Travelers reports Q3 return on equity of 12.1%, core return on equity 13.5% TRV Travelers $145.04 / +1.5 (+1.05%) 01/04/21 JPMorgan Travelers price target raised to $136 from $129 at JPMorgan 11/27/20 MKM Partners Travelers price target raised to $160 from $140 at MKM Partners 11/17/20 Barclays Travelers initiated with an Overweight at Barclays 10/29/20 BofA Chubb upgraded to Neutral at BofA with valuation gap to Travelers narrowed TRV Travelers $145.04 / +1.5 (+1.05%) 06:57 Today Travelers reports Q4 core EPS $4.91, consensus $3.18 10/20/20 Travelers reports Q3 core EPS $3.12, consensus $3.00 07/23/20 Travelers reports Q2 core EPS (20c), consensus (20c) 07/23/20 Travelers reports Q2 core EPS (20c), consensus (20c) TRV Travelers $145.04 / +1.5 (+1.05%) 01/20/21 Notable companies reporting before tomorrow's open 01/20/21 Notable companies reporting before tomorrow's open TRV Travelers $145.04 / +1.5 (+1.05%) 10/20/20 Fly Intel: Wall Street's top stories for Tuesday 10/20/20 Fly Intel: Wall Street's top stories at midday 10/20/20 Fly Intel: Pre-market Movers 07/23/20 Fly Intel: Wall Street's top stories for Thursday 09:00 Today Travelers - TRV
Hot Stocks	KeyCorp sees long-term ROTCE 16%-19%, cash efficiency ratio 54%-56% » 07:09 01/21/21 01/21 07:09 01/21/21 07:09 KEY KeyCorp $18.29 / -0.26 (-1.40%) Sees positive operating… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options KEY KeyCorp $18.29 / -0.26 (-1.40%) 07:08 Today KeyCorp sees FY21 NII relatively stable, including ongoing PPP participation 06:36 Today KeyCorp announces up to $900M share repurchase program 12/03/20 Accenture names former KeyCorp CEO Mooney to board 10/21/20 KeyCorp expects to be back on path to achieving LT targets KEY KeyCorp $18.29 / -0.26 (-1.40%) 01/06/21 Deutsche Bank KeyCorp price target raised to $18 from $14 at Deutsche Bank 01/04/21 Barclays KeyCorp price target raised to $20 from $15 at Barclays 10/26/20 Fly Intel: Top five analyst downgrades 10/26/20 Wedbush KeyCorp downgraded to Neutral on valuation, headwinds at Wedbush KEY KeyCorp $18.29 / -0.26 (-1.40%) 06:34 Today KeyCorp reports Q4 EPS 56c, consensus 43c 10/21/20 KeyCorp reports Q3 EPS 41c, consensus 37c 10/20/20 Notable companies reporting before tomorrow's open 10/20/20 Notable companies reporting before tomorrow's open KEY KeyCorp $18.29 / -0.26 (-1.40%) 01/20/21 Notable companies reporting before tomorrow's open 01/20/21 Notable companies reporting before tomorrow's open 08/15/20 PNC, KeyCorp among large regional banks offering steady dividends, Barron's says KEY KeyCorp $18.29 / -0.26 (-1.40%) 10/26/20 Apple coverage reinstatement, KeyCorp downgrade among top calls on Wall Street 07/22/20 Fly Intel: Pre-market Movers 03/01/21 26th Annual Energy Virtual Summit 10:00 Today KeyCorp - KEY KEY KeyCorp $18.29 / -0.26 (-1.40%) 08/11/20 KeyCorp call volume above normal and directionally bullish
Hot Stocks	KeyCorp sees FY21 NII relatively stable, including ongoing PPP participation » 07:08 01/21/21 01/21 07:08 01/21/21 07:08 KEY KeyCorp $18.29 / -0.26 (-1.40%) Sees FY21 noninterest… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options KEY KeyCorp $18.29 / -0.26 (-1.40%) 06:36 Today KeyCorp announces up to $900M share repurchase program 12/03/20 Accenture names former KeyCorp CEO Mooney to board 10/21/20 KeyCorp expects to be back on path to achieving LT targets 10/21/20 KeyCorp has decided to discontinue originating indirect auto loans KEY KeyCorp $18.29 / -0.26 (-1.40%) 01/06/21 Deutsche Bank KeyCorp price target raised to $18 from $14 at Deutsche Bank 01/04/21 Barclays KeyCorp price target raised to $20 from $15 at Barclays 10/26/20 Fly Intel: Top five analyst downgrades 10/26/20 Wedbush KeyCorp downgraded to Neutral on valuation, headwinds at Wedbush KEY KeyCorp $18.29 / -0.26 (-1.40%) 06:34 Today KeyCorp reports Q4 EPS 56c, consensus 43c 10/21/20 KeyCorp reports Q3 EPS 41c, consensus 37c 10/20/20 Notable companies reporting before tomorrow's open 10/20/20 Notable companies reporting before tomorrow's open KEY KeyCorp $18.29 / -0.26 (-1.40%) 01/20/21 Notable companies reporting before tomorrow's open 01/20/21 Notable companies reporting before tomorrow's open 08/15/20 PNC, KeyCorp among large regional banks offering steady dividends, Barron's says KEY KeyCorp $18.29 / -0.26 (-1.40%) 10/26/20 Apple coverage reinstatement, KeyCorp downgrade among top calls on Wall Street 07/22/20 Fly Intel: Pre-market Movers 03/01/21 26th Annual Energy Virtual Summit 10:00 Today KeyCorp - KEY KEY KeyCorp $18.29 / -0.26 (-1.40%) 08/11/20 KeyCorp call volume above normal and directionally bullish
Hot Stocks	Microbot Medical announces additions to Scientific Advisory Board » 07:08 01/21/21 01/21 07:08 01/21/21 07:08 MBOT Microbot Medical $8.21 / +0.13 (+1.61%) Microbot Medical… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly MBOT Microbot Medical $8.21 / +0.13 (+1.61%) 01/14/21 Microbot announces results of additional animal feasibility study with LIBERTY 11/17/20 Microbot Medical receives patents in multiple jursidictions 10/07/20 Microbot Medical receives notice of allowance for U.S. patent 08/17/20 Microbot Medical concludes Liberty Robotic System feasibility animal study MBOT Microbot Medical $8.21 / +0.13 (+1.61%) 08/18/20 H.C. Wainwright Microbot Medical price target raised to $20 from $19 at H.C. Wainwright 05/01/20 H.C. Wainwright Microbot Medical price target lowered to $19 from $26 at H.C. Wainwright MBOT Microbot Medical $8.21 / +0.13 (+1.61%) 11/25/20 Fly Intel: After-Hours Movers

Recommendations	Seagate price target raised to $60 from $41 at Barclays » 07:08 01/21/21 01/21 07:08 01/21/21 07:08 STX Seagate $61.43 / +0.23 (+0.38%) Barclays analyst Thomas… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options STX Seagate $61.43 / +0.23 (+0.38%) 01/19/21 Nidec files patent infringement suit against Seagate 12/28/20 Seagate appoints Prat Bhatt to Board of Directors 12/16/20 Intel announces next generation of memory and storage products 11/05/20 Climb Channel Solutions adds Seagate data storage systems to distribution line STX Seagate $61.43 / +0.23 (+0.38%) 01/20/21 Wedbush Seagate price target raised to $56 from $47 at Wedbush 01/19/21 Northland Seagate price target raised to $72 from $65 at Northland 01/19/21 Loop Capital Seagate price target raised to $70 from $60 at Loop Capital 12/31/20 KeyBanc Industry data points to flat monthly contract pricing for DRAM, says KeyBanc STX Seagate $61.43 / +0.23 (+0.38%) 10/22/20 Seagate sees Q2 adjusted EPS $1.10, plus/minus 15c, consensus $1.08 10/22/20 Seagate reports Q1 adjusted EPS 93c, consensus 88c 10/22/20 Notable companies reporting after market close 10/22/20 Fly Intel: What to watch in data storage earnings reports STX Seagate $61.43 / +0.23 (+0.38%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 10/23/20 Fly Intel: Wall Street's top stories for Friday 10/23/20 Fly Intel: Wall Street's top stories at midday 10/23/20 Fly Intel: Pre-market Movers 16:30 Today Seagate - STX STX Seagate $61.43 / +0.23 (+0.38%) 12/28/20 Largest borrow rate increases among liquid names 12/21/20 Seagate call volume above normal and directionally bullish 12/01/20 Seagate call volume above normal and directionally bullish 10/22/20 Seagate put volume heavy and directionally bearish
Recommendations	Western Digital price target raised to $46 from $42 at Barclays » 07:07 01/21/21 01/21 07:07 01/21/21 07:07 WDC Western Digital $51.84 / -0.14 (-0.27%) Barclays analyst Thomas… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WDC Western Digital $51.84 / -0.14 (-0.27%) 12/16/20 Intel announces next generation of memory and storage products 11/12/20 Twist, Illumina, Western Digital partner with Microsoft over DNA data storage 10/26/20 Dropbox among first to qualify Western Digital's new SMR HDDs 10/16/20 Video game hardware spending rose 15% year-over-year in September, says NPD WDC Western Digital $51.84 / -0.14 (-0.27%) 01/07/21 Stifel Western Digital price target raised to $64 from $54 at Stifel 12/31/20 KeyBanc Industry data points to flat monthly contract pricing for DRAM, says KeyBanc 12/28/20 Mizuho Western Digital price target raised to $59 from $57 at Mizuho 12/18/20 Wells Fargo Western Digital price target raised to $65 from $55 at Wells Fargo WDC Western Digital $51.84 / -0.14 (-0.27%) 10/28/20 Western Digital sees Q2 EPS 40c-60c, consensus 64c 10/28/20 Western Digital reports Q1 EPS 65c, consensus 54c 10/28/20 Notable companies reporting after market close 10/22/20 Fly Intel: What to watch in data storage earnings reports WDC Western Digital $51.84 / -0.14 (-0.27%) 12/03/20 U.S. in talks with Huawei CFO to settle charges, WSJ reports 11/23/20 U.K. considers Huawei installation ban in 2021, Bloomberg says 11/23/20 U.K. considers Huawei installation ban in 2021, Bloomberg says 10/20/20 Swedish regulators ban Huawei, ZTE from upcoming 5G networks, Reuters reports WDC Western Digital $51.84 / -0.14 (-0.27%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 10/28/20 Fly Intel: After-Hours Movers 10/19/20 Fly Intel: Wall Street's top stories for Monday 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 02/11/21 Technology & Internet Virtual Conference 01/28/21 Western Digital - WDC WDC Western Digital $51.84 / -0.14 (-0.27%) 12/31/20 Early notable gainers among liquid option names on December 31st 12/30/20 Unusually active option classes on open December 30th 12/01/20 Western Digital call volume above normal and directionally bullish 12/01/20 Early notable gainers among liquid option names on December 1st
Hot Stocks	Apellis says 'on track' for Phase 3 GA results in 3Q21 » 07:07 01/21/21 01/21 07:07 01/21/21 07:07 APLS Apellis $49.81 / -2.67 (-5.09%) Apellis Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events APLS Apellis $49.81 / -2.67 (-5.09%) 12/10/20 Swedish Orphan Biovitrum, Apellis report results from PEGASUS study 12/10/20 Apellis and Sobi report top-line Phase 3 results of pegcetacoplan in PNH 12/07/20 Apellis announces new analyses from Phase 3 PEGASUS study 11/19/20 Swedish Orphan Biovitrum, Apellis announce first patient dosed in MERIDIAN study APLS Apellis $49.81 / -2.67 (-5.09%) 12/14/20 Roth Capital Apellis price target raised to $73 from $50 at Roth Capital 12/10/20 Cowen Apellis price target raised to $55 from $45 at Cowen 12/04/20 JPMorgan Apellis price target raised to $87 from $50 at JPMorgan 12/01/20 BMO Capital Apellis price target raised to $66 from $57 at BMO Capital APLS Apellis $49.81 / -2.67 (-5.09%) 11/02/20 Apellis reports Q3 EPS ($1.79), consensus ($1.58) 07/31/20 Apellis reports Q2 EPS ($1.57), consensus ($1.39) APLS Apellis $49.81 / -2.67 (-5.09%) 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Fly Intel: Wall Street's top stories at midday 05/14/21 PDUFA Date for Pegcetacoplan
Hot Stocks	Mytheresa to begin trading on NYSE on January 21 » 07:07 01/21/21 01/21 07:07 01/21/21 07:07 MYTE Mytheresa $0.00 / + (+0.00%) MYT Netherlands Parent… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Syndicate On The Fly 21 Jan MYTE Mytheresa $0.00 / + (+0.00%) 01/17/21 Opening Day: Poshmark surges in debut, PetCo soars in return to market
Recommendations	Varonis price target raised to $175 from $150 at Barclays » 07:06 01/21/21 01/21 07:06 01/21/21 07:06 VRNS Varonis $183.01 / +2.75 (+1.53%) Barclays analyst Saket… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VRNS Varonis $183.01 / +2.75 (+1.53%) 01/19/21 Varonis announces new features for Varonis Data Security Platform VRNS Varonis $183.01 / +2.75 (+1.53%) 01/05/21 Piper Sandler Varonis price target raised to $180 from $140 at Piper Sandler 12/18/20 Truist Varonis price target raised to $160 from $145 at Truist 12/17/20 Barclays Varonis downgraded to Equal Weight with $150 target at Barclays 12/17/20 Barclays Varonis downgraded to Equal Weight from Overweight at Barclays VRNS Varonis $183.01 / +2.75 (+1.53%) 10/27/20 Varonis reports Q3 non-GAAP EPS 6c, consensus (13c) 10/26/20 Varonis sees Q4 EPS 10c-13c, consensus (2c) 08/03/20 Varonis sees Q3 EPS (14c)-(11c), consensus (16c) 08/03/20 Varonis reports Q2 EPS (77c), consensus (35c) VRNS Varonis $183.01 / +2.75 (+1.53%) 10/27/20 Foot Locker, DocuSign initiations among today's top calls on Wall Street 10/26/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers 02/08/21 Varonis - VRNS

Recommendations	BNY Mellon price target raised to $49 from $43 at RBC Capital » 07:06 01/21/21 01/21 07:06 01/21/21 07:06 BK BNY Mellon $42.51 / -3.3 (-7.20%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events BK BNY Mellon $42.51 / -3.3 (-7.20%) 01/19/21 BNY Mellon to implement data management platform for Janus Henderson 01/13/21 BNY Mellon, Amundi announce strategic alliance 12/18/20 BNY Mellon to resume share buyback program in 1Q21 12/16/20 Guardian Capital to acquire BNY Mellon's Canadian wealth management business BK BNY Mellon $42.51 / -3.3 (-7.20%) 06:29 Today Citi BNY Mellon earnings selloff a 'bit overdone,' says Citi 01/11/21 Citi BNY Mellon upgraded to Buy from Neutral at Citi 01/11/21 Citi BNY Mellon upgraded to Buy from Neutral at Citi 01/11/21 Piper Sandler BNY Mellon price target raised to $47 from $40 at Piper Sandler BK BNY Mellon $42.51 / -3.3 (-7.20%) 01/20/21 BNY Mellon reports Q4 ex-items EPS 96c, consensus 91c 01/19/21 Notable companies reporting before tomorrow's open 01/19/21 Notable companies reporting before tomorrow's open 10/16/20 BNY Mellon reports Q3 EPS 98c, consensus 94c BK BNY Mellon $42.51 / -3.3 (-7.20%) 10/06/20 BNY Mellon, NCB Capital enter deal for expansion in Saudi Arabia, Bloomberg says 09/21/20 Global banks moved allegedly illegal funds, Reuters reports 09/21/20 JPMorgan, other banks moved large sums of illicit cash, ICIJ reports 08/26/20 BNY Mellon: Majority of employees can work remotely until Jan., Bloomberg says BK BNY Mellon $42.51 / -3.3 (-7.20%) 11/30/20 Apple upgrade, Slack downgrade among today's top calls on Wall Street 11/10/20 Square, Wayfair upgrades among today's top calls on Wall Street 09/21/20 Fly Intel: Wall Street's top stories for Monday 09/21/20 Fly Intel: Wall Street's top stories at midday 02/24/21 22nd Annual Virtual Financial Services Forum 02/01/21 BNY Mellon
Hot Stocks	INmune Bio says XPro1595 found to decrease nueroinflammation biomarkers » 07:06 01/21/21 01/21 07:06 01/21/21 07:06 INMB INmune Bio $25.09 / -1.61 (-6.03%) INmune Bio announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events INMB INmune Bio $25.09 / -1.61 (-6.03%) 01/13/21 INmune Bio to host KOL webinar on Phase 1b trial of XPro1595 11/09/20 INmune Bio doses first patient in Phase 2 trial of Quellor 10/05/20 INmune Bio presents preliminary Phase 1 data in AD patients 09/16/20 INmune Bio awarded $2.9M NIH SBIR grant to support Phase 2 study of XPro1595 INMB INmune Bio $25.09 / -1.61 (-6.03%) 09/01/20 BTIG INmune Bio initiated with a Buy at BTIG 07/14/20 Roth Capital INmune Bio price target raised to $26 from $13 at Roth Capital 03/12/20 H.C. Wainwright INmune Bio price target lowered to $8 from $11 at H.C. Wainwright 03/11/20 Roth Capital INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital INMB INmune Bio $25.09 / -1.61 (-6.03%) 11/05/20 INmune Bio reports Q3 EPS (36c), consensus (17c) 16 Jul 03/15/21 33rd Annual Roth Virtual Conference
Recommendations	PTC price target raised to $142 from $130 at Barclays » 07:05 01/21/21 01/21 07:05 01/21/21 07:05 PTC PTC $130.41 / +4.86 (+3.87%) Barclays analyst Saket… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PTC PTC $130.41 / +4.86 (+3.87%) 12/14/20 PTC to acquire Arena Solutions for $715M in cash 11/10/20 PTC names Troy Richardson as COO 10/28/20 PTC, Rockwell Automation extend strategic alliance 09/08/20 Teradata promotes Hillary Ashton to chief product officer PTC PTC $130.41 / +4.86 (+3.87%) 01/12/21 Mizuho PTC price target raised to $150 from $130 at Mizuho 12/21/20 Deutsche Bank PTC price target raised to $132 from $120 at Deutsche Bank 12/16/20 Needham PTC price target raised to $125 from $100 at Needham 12/16/20 Loop Capital PTC price target raised to $140 from $110 at Loop Capital PTC PTC $130.41 / +4.86 (+3.87%) 12/16/20 PTC Q1 ARR tracking to midpoint of $1.28B-$1.32B guidance range 10/28/20 PTC sees FY21 non-GAAP EPS $2.65-$2.85, consensus $2.83 10/28/20 PTC reports Q4 non-GAAP EPS 78c, consensus 55c 10/28/20 PTC reports Q4 non-GAAP EPS 78c, consensus 55c PTC PTC $130.41 / +4.86 (+3.87%) 12/09/20 JPMorgan downgrades Zoom, upgrades Autodesk in software ratings shakeup 07/29/20 Fly Intel: After-Hours Movers 01/27/21 PTC - PTC 02/10/21 PTC Inc
Earnings	Baker Hughes reports Q4 adjusted EPS (7c), consensus 17c » 07:05 01/21/21 01/21 07:05 01/21/21 07:05 BKR Baker Hughes $22.91 / +0.03 (+0.13%) Reports Q4 revenue $5.5B,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events BKR Baker Hughes $22.91 / +0.03 (+0.13%) 01/15/21 Baker Hughes reports U.S. rig count up 13 to 373 rigs 01/15/21 Baker Hughes reports U.S. rig count up 13 to 373 rigs 01/08/21 Baker Hughes reports U.S. rig count up 9 to 360 rigs 01/08/21 Baker Hughes reports U.S. rig count up 9 to 360 rigs BKR Baker Hughes $22.91 / +0.03 (+0.13%) 01/13/21 JPMorgan JPMorgan announces top 10 energy picks for 2021 01/08/21 Barclays Baker Hughes downgraded to Equal Weight from Overweight at Barclays 12/18/20 JPMorgan Baker Hughes price target raised to $23 from $20 at JPMorgan 12/15/20 Citi Baker Hughes downgraded to Neutral from Buy at Citi BKR Baker Hughes $22.91 / +0.03 (+0.13%) 10/21/20 Baker Hughes reports Q3 EPS 4c, consensus 4c 10/20/20 Notable companies reporting before tomorrow's open 10/20/20 Notable companies reporting before tomorrow's open 07/22/20 Baker Hughes reports Q2 adj. EPS (5c), consensus 0c BKR Baker Hughes $22.91 / +0.03 (+0.13%) 11/11/20 OPEC+ discussing possible 3-to-6 month delay of production hikes, Bloomberg says BKR Baker Hughes $22.91 / +0.03 (+0.13%) 10/21/20 Fly Intel: Pre-market Movers 03/01/21 26th Annual Energy Virtual Summit 09:00 Today Baker Hughes - BKR
Hot Stocks	Golden Nugget Online launching online casino and sports betting in Michigan » 07:05 01/21/21 01/21 07:05 01/21/21 07:05 GNOG Golden Nugget Online $20.89 / +0.48 (+2.35%) Golden Nugget Online has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Options GNOG Golden Nugget Online $20.89 / +0.48 (+2.35%) 01/13/21 Benchmark Golden Nugget Online initiated with a Buy at Benchmark GNOG Golden Nugget Online $20.89 / +0.48 (+2.35%) 01/19/21 Largest borrow rate increases among liquid names

Hot Stocks	Sutro Biopharma says first patient dosed in dose-expansion study of STRO-002 » 07:05 01/21/21 01/21 07:05 01/21/21 07:05 STRO Sutro Biopharma $26.45 / -0.48 (-1.78%) Sutro Biopharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options STRO Sutro Biopharma $26.45 / -0.48 (-1.78%) 12/07/20 Sutro presents data from ongoing Phase 1 dose-escalation study for STRO-001 12/03/20 Sutro Biopharma jumps 20% to $20.38 after 'encouraging' STRO-002 ph.1 data 12/03/20 Sutro Biopharma's saw 'encouraging' phase 1 data for STRO-002 in ovarian cancer 09/09/20 Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer STRO Sutro Biopharma $26.45 / -0.48 (-1.78%) 12/02/20 Stifel Sutro Biopharma initiated with a Buy at Stifel 11/06/20 Piper Sandler Sutro Biopharma price target raised to $22 from $20 at Piper Sandler 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/02/20 Jefferies Sutro Biopharma initiated with a Buy at Jefferies STRO Sutro Biopharma $26.45 / -0.48 (-1.78%) 11/05/20 Sutro Biopharma reports Q3 EPS 45c, consensus (51c) 08/06/20 Sutro Biopharma reports Q2 EPS (94c), consensus (64c) 09 Dec 12 May STRO Sutro Biopharma $26.45 / -0.48 (-1.78%) 12/07/20 Fly Intel: After-Hours Movers 12/04/20 Fly Intel: Wall Street's top stories for Friday 12/04/20 Fly Intel: Wall Street's top stories at midday 12/03/20 Fly Intel: After-Hours Movers STRO Sutro Biopharma $26.45 / -0.48 (-1.78%) 11/09/20 Eleven new option listings and two option delistings on November 9th
General news	FX Update: The DXY dollar index edged out a six-day low » 07:05 01/21/21 01/21 07:05 01/21/21 07:05 FX Update: The DXY dollar… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Recommendations	Ping Identity price target raised to $35 from $31 at Barclays » 07:04 01/21/21 01/21 07:04 01/21/21 07:04 PING Ping Identity $32.90 / +2.7 (+8.94%) Barclays analyst Saket… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PING Ping Identity $32.90 / +2.7 (+8.94%) 11/05/20 Ping Identity falls -15.9% 11/05/20 Ping Identity falls -15.0% 11/02/20 Ping Identity announces the acquisition of Symphonic Software 10/07/20 Ping Identity acquires ShoCard, terms undisclosed PING Ping Identity $32.90 / +2.7 (+8.94%) 01/12/21 Mizuho Ping Identity price target raised to $32 from $29 at Mizuho 01/08/21 Goldman Sachs Ping Identity upgraded to Buy from Neutral at Goldman Sachs 01/05/21 Piper Sandler Ping Identity price target raised to $30 from $25 at Piper Sandler 12/21/20 Mizuho Mizuho sees more security spending following SolarWinds 'mega-breach' PING Ping Identity $32.90 / +2.7 (+8.94%) 11/04/20 Ping Identity sees Q4 revenue $67M-$70M, consensus $68.75M 11/04/20 Ping Identity reports Q3 EPS (1c), consensus 2c 08/12/20 Ping Identity sees Q3 revenue $54.0M-$57.0M, consensus $59.56M 08/12/20 Ping Identity reports Q2 EPS (4c), consensus 1c 15 Dec 09 Jul 14 May PING Ping Identity $32.90 / +2.7 (+8.94%) 12/21/20 Analysts move to sidelines on SolarWinds following cyberattack 11/04/20 Fly Intel: After-Hours Movers 02/24/21 Ping Identity - PING
Earnings	Sandy Spring Bancorp reports Q4 EPS $1.19, consensus 93c » 07:03 01/21/21 01/21 07:03 01/21/21 07:03 SASR Sandy Spring Bancorp $35.43 / -0.01 (-0.03%) At December 31, 2020, the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events SASR Sandy Spring Bancorp $35.43 / -0.01 (-0.03%) 12/17/20 Sandy Spring Bancorp announces stock repurchase program up to 2.35M shares SASR Sandy Spring Bancorp $35.43 / -0.01 (-0.03%) 12/09/20 Gabelli Sandy Spring Bancorp downgraded to Hold from Buy at Gabelli 12/09/20 Gabelli Sandy Spring Bancorp downgraded to Hold from Buy at Gabelli 08/03/20 Piper Sandler Sandy Spring Bancorp resumed with a Neutral at Piper Sandler 06/30/20 Stephens Sandy Spring Bancorp resumed with an Equal Weight at Stephens SASR Sandy Spring Bancorp $35.43 / -0.01 (-0.03%) 10/22/20 Sandy Spring Bancorp reports Q3 EPS (94c), consenus (71c) 07/23/20 Sandy Spring Bancorp reports Q2 EPS (31c), two est. 6c 14:00 Today Sandy Spring Bancorp - SASR
Hot Stocks	Engine Capital, Hawk Ridge express concerns with Adtalem Global Education » 07:03 01/21/21 01/21 07:03 01/21/21 07:03 ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) Engine Capital and Hawk… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) 01/15/21 California AG sues Education Department over for-profit collegerule easing 09/11/20 Adtalem to acquire Walden University from Laureate Education for $1.48B in cash 09/11/20 Laureate Education to sell Walden University to Adtalem Global Education ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) 11/06/20 Barrington Challenges facing Adtalem Global Education are temporary, says Barrington 08/19/20 Barrington Adtalem Global Education price target raised to $40 from $35 at Barrington ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) 11/05/20 Adtalem Global Education reports Q1 EPS 38c, consensus 40c 11/05/20 Adtalem Global Education sees FY21 EPS growth of 25%-30% 08/18/20 Adtalem Global Education reports Q4 EPS 58c, consensus 64c ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) 09/11/20 Adtalem Global near $1.5B deal to buy Walden from Laureate, Bloomberg says ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) 09/11/20 Fly Intel: Wall Street's top stories for Friday 09/11/20 Fly Intel: Wall Street's top stories at midday 08/18/20 Fly Intel: After-Hours Movers 02/02/21 Adtalem Global Education - ATGE ATGE Adtalem Global Education $38.36 / -0.28 (-0.72%) 08/18/20 Adtalem Global Education options imply 10.9% move in share price post-earnings

Events

Earnings calls, analyst events, roadshows and more

TAL
Today at 08:00

TAL Education - TAL Conference Calls
STL
Today at 08:00

Sterling Bancorp - STL Conference Calls
TFC
Today at 08:00

Truist Financial - TFC Conference Calls
SI
Today at 08:00

Silvergate Capital - SI Conference Calls
BEDU
Today at 08:00

Bright Scholar - BEDU Conference Calls
DFS
Today at 08:00

Discover - DFS Conference Calls
WNS
Today at 08:00

WNS Holdings - WNS Conference Calls
CTXS
Today at 08:15

Citrix - CTXS Conference Calls
PLXS
Today at 08:30

Plexus - PLXS Conference Calls
UNP
Today at 08:45

Union Pacific - UNP Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley Priced at: $25.50 700K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital Priced at: $30.50 4.59M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright Priced at: $17.50 5.484M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.90 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright Priced at: $2.40 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim Priced at: $6.00 33.333M Shares DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse Priced at: $11.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel Priced at: $22.00 15.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE Priced at: $11.50 4.99M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler Priced at: $14.00 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush Priced at: $13.00 9.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen Priced at: $26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities Priced at: $22.50 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright Priced at: $91.00 1.923M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading Priced at: $8.50 11.765M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler Priced at: $7.00 14.286M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel Priced at: $28.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse Priced at: $66.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS Priced at: $66.00 3.788M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INO X INO Inovio Spot Secondary Managers: BofA, Jefferies & Cantor Fitzgerald, Oppenheimer Priced at: $8.50 2.655M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.30 7.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance $8.00-10.00 116.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink $24.71 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ONCS X ONCS OncoSec Spot Secondary Managers: BTIG $5.76 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies $42.25 17.5M Shares CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen, & Stifel, Wedbush, Academy Securities $37.73 7.5M Shares DCBO X DCBO Docebo Secondary Managers: Morgan Stanley, Goldman Sachs & Canaccord $70.51 3.65M Shares NVTA X NVTA Invitae Secondary Managers: JPMorgan, Morgan Stanley, Cowen & SVB Leerink $56.93 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan $29.05 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SI X SI Silvergate Capital Secondary Managers: Goldman Sachs, Keefe Bruyette & Canaccord, Compass Point, Craig-Hallum $66.43 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

IV formulation of ibrexa 'a significant positive' for Scynexis, says Maxim

TODAY'S FREE FLY STORIES

Get Full Fly Access